After hours:
Chart Events
Performance Outlook
| Previous Close | 102.03 |
| Open | 102.39 |
| Bid | 106.47 x 800 |
| Ask | 108.80 x 1300 |
| Day's Range | 102.39 - 110.50 |
| 52 Week Range | 95.50 - 188.99 |
| Volume | |
| Avg. Volume | 685,714 |
| Market Cap | 26.049B |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | 5.34 |
| EPS (TTM) | 20.34 |
| Earnings Date | Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 161.76 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BNTX
Related Research
- BioNTech SEAnalyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic Moat2 months agoMorningstar
Motley Fool3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
BioNTech (NASDAQ: BNTX) has turned in a dismal performance so far this year. The average analysts' price target reflects an upside potential of 56%. Granted, not every analyst is all that bullish about BioNTech.
Motley FoolWhy Pfizer and BioNTech Stocks Zoomed Higher Today
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Motley FoolWhy CureVac Stock Plunged Today
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
